The analysis of efficacy and immunological response during nucleotide analogues-IFN sequential therapy for CHB patients

The analysis of efficacy and immunological response during nucleotide analogues-IFN sequential therapy for CHB patients - HBSEQ2

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010930

Enrollment

100

Registered

2013-06-11

Start date

2013-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. over 20 years olds 2. chronic hepatitis B patients 3. informed consents 4. The duration of nucleotide therapy for over two years is desirable.

Exclusion criteria

Exclusion criteria: The attending physician admits the patients who are not eligible.

Design outcomes

Primary

Measure	Time frame
The detection of immunological factors that can induce the stability of CH-B clinical condition	—

Countries

Japan

Contacts

Public ContactYasuteru Kondo

Tohoku University Hospital Gastroenterology

0022-717-7171

Outcome results